Cassava, former execs ink SEC deal to resolve allegations around misleading Alzheimer's data drop

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made misleading statements about phase 2b data on its Alzheimer’s disease drug candidate.